NEWSWIRETODAY Press Release & Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: AM Technology

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AM Technology Joins EU Funded Flow Chemistry Project - AM Technology are collaborating on an EU funded project to develop and scale up flow chemistry methods for the manufacture of pharmaceutical APIs
AM Technology Joins EU Funded Flow Chemistry Project

 

NewswireTODAY - /newswire/ - Runcorn, Cheshire, United Kingdom, 2009/09/13 - AM Technology are collaborating on an EU funded project to develop and scale up flow chemistry methods for the manufacture of pharmaceutical APIs.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

AM Technology are pleased to announce their participation in a project to develop flow processes for industrial synthesis of pharmaceutical compounds. The ‘Pharmagen project’ is being coordinated by Serichim Srl and has other five partners; Flamma SA, Apotechnia SA, Carbopharm GbmH, PSE Ltd and LD&TI Sri. This work is being funded by the EU Commision DG Research within the VII Framework Program for Research and Development.

Global manufacturing costs, for pharmaceutical products in 2008 exceeded $200 billion. Greater use of flow chemistry within the industry will bring substantial benefits in terms of reduced manufacturing costs, lower carbon footprints and less pollution. Developing flow chemistry techniques for industrial pharmaceutical processes however faces a variety of technical and regulatory hurdles. The Pharmagen project will use a multi disciplinary approach for tackling these problems.

“Simultaneously controlling axial dispersion, mixing rate and reaction time in flow reactors can be very difficult, particularly where there is more than one phase” Said Robert Ashe of AM Technology. “This project brings together an outstanding combination of skills from manufacturing, simulation, engineering and chemistry. This approach will greatly accelerate the problem solving process in what is a complex area of process control”.

AM Technology (amtechuk.com) were selected as partners on this project for their experience and knowhow in reactor design. Based in Cheshire UK, they have extensive experience in the design and construction of both batch and continuous reactions. Their patented Coflore ACR (Agitated Cell Reactor) is the first truly modular multi stage CSTR and represents a breakthrough in flow reactor design. Dynamic mixers combined with multiple reaction stages, give the ACR outstanding mixing, plug flow and great versatility. The ACR is ideal for multi phase mixtures and its inherently low pressure drop characteristics simplify selection and calibration of the flow pumps.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: AM Technology

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AM Technology Joins EU Funded Flow Chemistry Project

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Robert Ashe - AMTechUK.com 
+44(0)19 2823 7420 sales[.]amtechuk.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AM Technology securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AM Technology / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

JFCR, NEC, and Taiho to Develop Cancer Vaccines Utilizing Whole-Genome Information
Ono Receives Supplemental Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer
WuXi AppTec Receives Frost & Sullivan’s 2025 Global Company of the Year Recognition in the CRDMO Industry
Frost Radar™ Identifies Top Growth and Innovation Leaders in Pharmaceutical and Biotech Laboratory Information Management Systems
Ono Submits an Application for Approval of Cenobamate (ONO-2017), Antiseizure Medications in Japan
Viva Biotech Receives Frost & Sullivan’s 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry
Biotech Firm 4Dcell Selected to Showcase Next-Gen Cardiac Drug Testing Platform At EIC Corporate Day
Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
Ono and Bristol-Myers Squibb KK Receive Supplemental Approval of Opdivo and Yervoy in Combination Therapy in Japan
Ono Enters into A Definitive Agreement with Seikagaku for Co-development and Marketing Collaboration on Gel-One for the Treatment of Osteoarthritis
Deciphera Announces Positive CHMP Opinion for ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
Novotech Earns Frost & Sullivan’s 2025 Global Company of the Year Recognition for Excellence in Biotech Clinical Research Services
Ono Pharmaceutical and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
NEC and Chugai Pharmaceutical Use AI to Potentially Enhance Cancer Treatment
BASF Strengthens its Commitment to the Biopharma and Pharmaceutical Ingredients Industries through A New Investment in North America

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  Limelon Advertising, Co.





 
  ©2005-2025 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)